Medication info
Sevirucca Tablet 5/40 mg (Amlodipine, Olmesartan)

Sevirucca Tablet 5/40 mg (Amlodipine, Olmesartan)

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pale yellow circular film-coated tablets
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 202003823 · Approved 2020.05.26 · Insurance code 694004490

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before starting this medication. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medication may be considered. The maximum dose of this medication is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2, “Patients who should not receive this medication,” under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
∘Children: The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower and control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with Amlodipine or Olmesartan Medoxomil. It helps reduce the risk of cardiovascular complications and improves patient health.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before starting this medication. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medication may be considered. The maximum dose of this medication is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2, “Patients who should not receive this medication,” under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

∘Children: The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimester of pregnancy; thus, it must be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with hypersensitivity to its active ingredients or in pregnant or nursing women, patients with severe liver impairment, patients with severe valvular heart disease, patients with biliary obstruction, patients undergoing renal dialysis, patients in a state of shock, and certain diabetes patients. Caution should be taken with patients who are deficient in fluids or salt as hypotension may occur; careful monitoring of their condition is required. Patients sensitive to vascular dilation should be cautious as hypotension may occur due to vasodilation. Patients with severe obstructive coronary artery disease must be careful as their symptoms may worsen. Heart failure patients should closely monitor their heart status while using this drug, and patients with impaired renal function should carefully monitor changes in kidney function. For patients with reduced liver function, caution is necessary as drug metabolism may be delayed. During the treatment with this drug, side effects such as dizziness, headache, hypotension, orthostatic hypotension, fatigue, edema, dyspepsia, and rash may occur, and any unusual symptoms should be discussed with a physician. Especially, this drug may increase blood potassium levels, and patients at risk of hyperkalemia should undergo regular blood tests. Taking this medication during pregnancy can result in serious issues such as fetal kidney damage, anuria, and hypotension; thus, alternative treatments should be considered if there are plans for pregnancy or if already pregnant. Nursing mothers are recommended to either discontinue breastfeeding or stop taking this medication, as it may pass into breast milk and affect the baby. This drug is not recommended for children under 18 as its safety and efficacy have not been established in this age group. Elderly patients should be administered with caution, starting from a low dose considering any decline in liver, kidney, or heart function and accompanying diseases. In case of overdose, symptoms such as severe hypotension, vasodilation, and tachycardia may occur, requiring immediate monitoring of heart function and respiration in a hospital with appropriate treatment. Taking this medication with grapefruit juice may excessively enhance blood pressure-lowering effects, so concomitant use should be avoided. This medication may interact with other drugs, so it is essential to inform the doctor or pharmacist about any medications currently being taken. Store this medication securely out of reach of children, avoiding exposure to direct sunlight and moisture.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory depression
  • syncope
Show 92 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pit edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • elevated gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • stroke deterioration
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute kidney failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • elevated serum creatinine
  • urticaria
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is also best stored at room temperature between 1 degree and 30 degrees Celsius. Proper storage maintains the medication's effectiveness.

Appearance and packaging

Appearance

Pale yellow circular film-coated tablets

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.